Japan court reviews Boehringer diabetes patent after JPO upholds combination therapy claims
Japan’s Intellectual Property High Court is reviewing a decision by the Japan Patent Office that upheld Boehringer Ingelheim’s patent for a type 2 diabetes treatment involving a DPP-4 inhibitor used in...To view the full article, register now.
Already a subscriber? Click here to view full article